Natco Pharma Ltd. share price target

Natcos (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 428 crs, which is 5% higher than our estimates. The strong uptick in numbers has been primarily on account of incremental profit...

EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to | 137 crore (I-direct estimate: | 109 crore) Adjusted net profit increased 96% YoY to | 93 crore (I-direct...

Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter.

Natco Pharmaceuticals Ltd (NPL) continues to deliver on near-term expectations while simultaneously building up pipeline for a sustainable future growth.

Higher gTamiflu profit share (increased market share and stronger flu season) pushed Q4FY17 EBITDA to Rs 2.4bn, up 159% YoY and 22% above our estimate (despite Rs 600mn one-time expense).

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 577 crs, which was 5% higher than our estimates of INR 550 crs. The strong uptick in numbers was primarily on account of profit...

EBITDA margins improved 1810 bps YoY to 41.7% (I-direct estimates: 38.5%) mainly due to Oseltamivir exclusivity. EBITDA grew 159% to | 241 crore (I-direct estimate: | 215 crore) Adjusted net profit increased 178% YoY to | 177 crore (I-direct...

Natco Pharmaceuticals (Natco) is a R&D focused player with strong focus on oncology and hepatology. The company is a market leader in the domestic generic oncology space with 23% market share.

Natco Pharma is a Hyderabad based pharma company with focus on limited competition and high margin products. It has presence in domestic and global markets and has two main business segments i.e. API and Formulations. Natco's topline and bottomline is set to grow at 36% and 61% CAGR over FY16-FY19E due to 1) strong performance of domestic..